146 related articles for article (PubMed ID: 38500360)
1. A Potent Neutralizing Monoclonal Antibody to Human Growth Hormone Suppresses Insulin-Like Growth Factor-1 in Female Rats.
Hata T; Uematsu Y; Sugita A; Adachi H; Kato S; Hirate M; Ishikura KI; Kaku A; Ohara H; Kojima N; Takahashi T; Kurokawa T
Endocrinology; 2024 Mar; 165(5):. PubMed ID: 38500360
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of long-acting pasireotide in Japanese patients with acromegaly or pituitary gigantism: results from a multicenter, open-label, randomized, phase 2 study.
Tahara S; Murakami M; Kaneko T; Shimatsu A
Endocr J; 2017 Jul; 64(7):735-747. PubMed ID: 28592706
[TBL] [Abstract][Full Text] [Related]
3. Efficacy, safety, and pharmacokinetics of sustained-release lanreotide (lanreotide Autogel) in Japanese patients with acromegaly or pituitary gigantism.
Shimatsu A; Teramoto A; Hizuka N; Kitai K; Ramis J; Chihara K
Endocr J; 2013; 60(5):651-63. PubMed ID: 23337477
[TBL] [Abstract][Full Text] [Related]
4. Acromegalic gigantism with low serum level of growth hormone and elevated serum insulin-like growth factor-I.
Miyazaki R; Yoshida T; Sakane N; Yasuda T; Umekawa T; Kondo M; Shimatsu A; Hizuka N; Sano T
Intern Med; 1995 Mar; 34(3):183-7. PubMed ID: 7787324
[TBL] [Abstract][Full Text] [Related]
5. Cardiac and metabolic effects of chronic growth hormone and insulin-like growth factor I excess in young adults with pituitary gigantism.
Bondanelli M; Bonadonna S; Ambrosio MR; Doga M; Gola M; Onofri A; Zatelli MC; Giustina A; degli Uberti EC
Metabolism; 2005 Sep; 54(9):1174-80. PubMed ID: 16125529
[TBL] [Abstract][Full Text] [Related]
6. Growth hormone (GH) secretory dynamics in a case of acromegalic gigantism associated with hyperprolactinemia: nonpulsatile secretion of GH may induce elevated insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 levels.
Yoshida T; Shimatsu A; Sakane N; Hizuka N; Horikawa R; Tanaka T
J Clin Endocrinol Metab; 1996 Jan; 81(1):310-3. PubMed ID: 8550769
[TBL] [Abstract][Full Text] [Related]
7. Digital analysis of hormonal immunostaining in pituitary adenomas classified according to WHO 2017 criteria and correlation with preoperative laboratory findings.
Tamanini JVG; Dal Fabbro M; de Freitas LLL; Vassallo J; de Souza Queiroz L; Rogerio F
Neurosurg Focus; 2020 Jun; 48(6):E12. PubMed ID: 32480373
[TBL] [Abstract][Full Text] [Related]
8. Bromocriptine, a dopamine agonist, increases growth hormone secretion in a patient with acromegaly.
Arihara Z; Sakurai K; Yamashita R; Niitsuma S; Ueno T; Yamamura N; Yamada S; Inoshita N; Takahashi K
Tohoku J Exp Med; 2014 Oct; 234(2):129-35. PubMed ID: 25253414
[TBL] [Abstract][Full Text] [Related]
9. A legendary sumo wrestler with gigantism or acromegaly? The case of Ikezuki Geitazaemon (1827-1850).
Takada K; Sasano M; Hayakawa S
Med Hypotheses; 2020 Nov; 144():110174. PubMed ID: 33254497
[TBL] [Abstract][Full Text] [Related]
10. [Long-term treatment of acromegaly and gigantism with octreotide (SMS 201-995)].
Shimatsu A; Imura H; Irie M; Nakagawa S; Goto Y; Shimizu N; Takeda R; Kato Y; Saito S; Ibayashi H
Nihon Naibunpi Gakkai Zasshi; 1992 Feb; 68(2):89-99. PubMed ID: 1592144
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological management of acromegaly: a current perspective.
Manjila S; Wu OC; Khan FR; Khan MM; Arafah BM; Selman WR
Neurosurg Focus; 2010 Oct; 29(4):E14. PubMed ID: 20887124
[TBL] [Abstract][Full Text] [Related]
12. Pegvisomant therapy in pituitary gigantism: successful treatment in a 12-year-old girl.
Rix M; Laurberg P; Hoejberg AS; Brock-Jacobsen B
Eur J Endocrinol; 2005 Aug; 153(2):195-201. PubMed ID: 16061823
[TBL] [Abstract][Full Text] [Related]
13. Cyproheptadine-mediated inhibition of growth hormone and prolactin release from pituitary adenoma cells of acromegaly and gigantism in culture.
Ishibashi M; Fukushima T; Yamaji T
Acta Endocrinol (Copenh); 1985 Aug; 109(4):474-80. PubMed ID: 2994332
[TBL] [Abstract][Full Text] [Related]
14. Potential markers of disease behavior in acromegaly and gigantism.
Hernández-Ramírez LC
Expert Rev Endocrinol Metab; 2020 May; 15(3):171-183. PubMed ID: 32372673
[No Abstract] [Full Text] [Related]
15. The pulsatile GH secretion in acromegaly: hypothalamic or pituitary origin?
Riedel M; Günther T; von zur Mühlen A; Brabant G
Clin Endocrinol (Oxf); 1992 Sep; 37(3):233-9. PubMed ID: 1358484
[TBL] [Abstract][Full Text] [Related]
16. [A multicenter clinical trial of SMS 201-995 (octreotide acetate) in acromegaly and gigantism].
Shimatsu A; Imura H; Irie M; Nakagawa S; Goto Y; Shimizu N; Takeda R; Kato Y; Saito S; Ibayashi H
Nihon Naibunpi Gakkai Zasshi; 1989 Jul; 65(7):640-52. PubMed ID: 2684694
[TBL] [Abstract][Full Text] [Related]
17. Regulation of human growth hormone secretion and its disorders.
Kato Y; Murakami Y; Sohmiya M; Nishiki M
Intern Med; 2002 Jan; 41(1):7-13. PubMed ID: 11838603
[TBL] [Abstract][Full Text] [Related]
18. Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly.
Colao A; Attanasio R; Pivonello R; Cappabianca P; Cavallo LM; Lasio G; Lodrini A; Lombardi G; Cozzi R
J Clin Endocrinol Metab; 2006 Jan; 91(1):85-92. PubMed ID: 16263832
[TBL] [Abstract][Full Text] [Related]
19. Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide Autogel therapy: a randomized, placebo-controlled, multicenter study with a 52 week open extension.
Melmed S; Cook D; Schopohl J; Goth MI; Lam KS; Marek J
Pituitary; 2010; 13(1):18-28. PubMed ID: 19639415
[TBL] [Abstract][Full Text] [Related]
20. Management of endocrine disease: GH excess: diagnosis and medical therapy.
Andersen M
Eur J Endocrinol; 2014 Jan; 170(1):R31-41. PubMed ID: 24144967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
